Systems and methods for dosing externally powered cortical stimulation (xcs) therapy

Externally powered stimulation therapies may be applied to a targeted region to modulate a physiological activity within a subject and to address one or more physiological conditions. The present disclosure relates to configuring a set of selection parameters based on data from a non-invasive technique, and rhythmic parameters or event-based parameters derived from physiological data of the subject for modulation of the physiological activity. The techniques, as disclosed herein, may initiate an externally powered cortical stimulation (XCS) therapy and a regenerated XCS therapy to the targeted region of the subject through a stimulation electrode, based on the set of selection parameters. The regenerated XCS therapy may be initiated after reconfiguring the set of selection parameters based on feedback from the subject following the delivery of the XCS therapy.

The abstract as published by the patent office, from US20260301912A1. It describes the invention; it is not a statement of what is protected.

• Interface and electrodes

  Electrodes and arrays

• Stimulation

  Stimulation · Closed loop

What the filing appears to be about, read by published rules from its title, abstract and classification codes (A61B5/293, A61B5/369, A61B5/377, A61B5/383, A61B5/4836). The claims define what a patent protects, and they are not read here.

Interface and electrodes

Everything downstream works with what the contacts pick up. Their number, size and distance from the neurons set the ceiling on the signal. The problem behind it: more contacts, closer to neurons, that still record after years in tissue that reacts to them.

Stimulation

Restoring sensation, sight or movement needs information going in, and a therapy that adapts needs to sense and stimulate at once. The problem behind it: evoking a precise, stable effect without damaging tissue or electrodes, and without blinding the recording.

Why the layer matters to the field, not a judgement of this filing. A patent family shows that protection was sought. It does not show that the technology was built, is used in a product, or works in people. The whole stack

One invention, published 2 times in 2 offices. Each publication opens in Espacenet.

• United StatesUS20260301912A11 Oct 2026
• International (PCT)a route to several countries, not a countryWO2026206599A11 Oct 2026

1. 25 Mar 2025First filingEarliest priority, at United States. The family is counted in this year.
2. 6 Mar 2026ApplicationsFiled at United States, International (PCT).
3. 1 Oct 2026First publicationUS20260301912A1, United States.

Dates as the offices published them. Records of lapses, withdrawals and changes of owner have not been read for this family, and whether a patent is in force today is not assessed.

Organisation

Motif Neurotech · 3 families identified

• Bibliographic data, family members and office records: European Patent Office, Open Patent Services (the DOCDB and INPADOC databases), read 7 Oct 2026.
• The record itself, with its claims and description: US20260301912A1 in Espacenet
• Counted as a BCI patent family: classified A61B5/293 (invasive electrodes for brain recording); filed by MOTIF NEUROTECH, INC., an organisation already in the graph; describes neural hardware or methods without naming the field. How families are found and judged